C-erbB2、PCNA、ER、PR在126例乳腺癌中的表达及临床意义

Expression and clinical significance of C-erbB2,PCNA,ER,PR in 126 cases of breast carcinoma

目的:研究C-erbB2、PCNA、ER、PR在乳腺癌中的表达及其与乳腺癌临床、病理因素之间的关系。方法:采用免疫组化SP法检测126例乳腺癌组织C-erbB2、PCNA、ER、PR蛋白的表达。结果:C-erbB2、pC-NA、ER、PR在乳腺癌阳性表达率分别为:36.5%,95.2%,65.1%,54%。C-erbB2、pCNA、ER、PR蛋白阳性表达率和表达强度与乳腺癌患者的年龄、淋巴结转移、肿瘤大小、pTNM分期差异性无统计学意义(P>0.05)。C-erbB2、PCNA与组织学分级差异具有统计学意义(P<0.05)。C-erbB2与ER、PR均呈负相关(r=-0.344,P=0.000;r=-0.226,P=0.011)。结论:C-erbB2,PCNA过表达者预后差,可以作为判断乳腺癌患者预后的有效指标。

Objective： To investigate the relationship between expression of C - erbB2, PCNA, ER, PR and clinic - pathologic characters of human breast carcinoma. Methods： The expressions of C - erbB2, PCNA, ER, PR were studied in 126 cases of breast carcinoma by using SP immunohistochemistry. Results：The positive rates of expression of C -erbB2 ,PCNA,ER,PR in breast carcinoma were 36.5% ,95.2% ,65.1% ,54% respectively. The positive rates and expression intensity of C - erbB2, PCNA, ER, PR in breast carcinoma had no significant correlation with the age, lymph node metastasis, tumor size,pTNM stage of the patient（P 〉 0.05）. The positive rates and expression intensity of C -erbB2, PCNA in breast carcinoma had significant correlation with the differentiation degree of the patient（P 〈 0.05 ）. The expression of C - erbB2 was negatively associated with ER, PR （ r = - 0. 344, P = 0. 000 ; r = - 0. 226, P = 0.011 ）. Conclusion：Over - expression of C - erbB2 and pCNA showed poor prognosis and they can be markers for estimating the prognosis of breast cancer.